Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus delbrueckii ssp. bulgaricus TCI904
- Development stage
- Preclinical
- Lead developer
- TCI
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
lactobacillus delbrueckii ssp. bulgaricus TCI904 is a specific probiotic bacterial strain isolated from naturally fermented milk. It is a lactic acid bacterium commonly used in yogurt production but developed as a probiotic ingredient for oral use. In animal models (mice), oral administration of TCI904 demonstrated reduction in fat and body weight accumulation, modulation of innate immunity (especially fecal IgA increase), improvement in metabolic indicators such as insulin resistance and lipid profiles, and linked anxiety reduction in high-fat diet-induced obesity. The mechanism of action primarily involves pancreatic lipase inhibition, immunomodulation (including enhancement of mucosal IgA), and potential metabolic effects, possibly including effects on gut microbiota and inflammatory signaling pathways. It was developed and studied by TCI Co. and academic partners. Safety for human oral consumption at recommended doses was demonstrated in animal studies[1].
- Other names
- Lactobacillus delbrueckii subsp. bulgaricus TCI904LDB TCI904
02
Targets
PNLIP (Pancreatic triacylglycerol lipase)IgA (Immunoglobulin A)
Beyond the preview
Go deeper on lactobacillus delbrueckii ssp. bulgaricus TCI904.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus delbrueckii ssp. bulgaricus TCI904.